|
Tumor Cell Invasion
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
In the end, it was proved that LINC01128 could enhance cell proliferation, migration and invasion as well as inhibit cell apoptosis by binding with miR-383-5p and upregulating SFN.
|
31779593 |
2019 |
|
Rumination Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
While no genome-wide significant hit emerged at the SNP level, the association of rumination survived correction for multiple testing with KCTD12 at the gene level, and with the set of genes binding miR-383 at the gene set level.
|
30886212 |
2019 |
|
Tumor Initiation
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
In view of our results, we propose that frequent loss of miR-383 at chr8p22 region leads to tumor initiation and prostate cancer metastasis.
|
27893706 |
2017 |
|
Hepatoma, Morris
|
0.300 |
Biomarker
|
disease |
CTD_human |
Circulating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from early stages.
|
21035526 |
2011 |
|
Hepatoma, Novikoff
|
0.300 |
Biomarker
|
disease |
CTD_human |
Circulating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from early stages.
|
21035526 |
2011 |
|
Liver Neoplasms, Experimental
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Circulating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from early stages.
|
21035526 |
2011 |
|
Experimental Hepatoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Circulating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from early stages.
|
21035526 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Also, the susceptibility of miR-383 as a tumor marker and the relationship between its aberrant expression and clinicopathological features were determined. qRT-PCR data showed that miR-383 was dysregulated during gastric tumorigenesis.
|
28243881 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The rates of tumor growth in vector-control group and blank group were significantly faster than that in U87-miR-383 group, and the average tumor volume and weight in vector-control group and blank group were increased as compared with U87-miR-383 group.
|
25936342 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In summary, this study suggested that miR-383 plays the role of tumor suppressor by targeting CCND1 in glioma cells, and may be useful for developing a new therapeutic strategy for gliomas.
|
25450356 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The present study concluded that miR-383-5p was downregulated and may act as a tumor suppressor in GC.
|
31637133 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo experiments also revealed that tumor growth could be inhibited by miR-383-5p mimic.
|
30399596 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The effects of miR-383 were mediated through targeting a tumor suppressor, interferon regulatory factor-1 (IRF1), and miR-383 was negatively correlated with IRF1 protein expression in vivo. miR-383 inhibited IRF1 by affecting its mRNA stability, which subsequently reduced the levels of the targets of IRF1, namely cyclin D1, CDK2 and p21.
|
21368870 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Besides, the addition of miR-383 decreased the tumor volume and size and inhibited the expressions of Wnt1, β-catenin, and cyclin D1 at the protein level in nude mice.
|
30426539 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, miR-383 serves as a tumor-suppressive miR to regulate cholangiocarcinoma cell proliferation, migration, and invasion via directly targeting IRF1.
|
30145803 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MicroRNA-383 is a tumor suppressor in human lung cancer by targeting endothelial PAS domain-containing protein 1.
|
27862077 |
2016 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, miR-383 serves as a tumor-suppressive miR to regulate cholangiocarcinoma cell proliferation, migration, and invasion via directly targeting IRF1.
|
30145803 |
2018 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Transfection with a miR-383 mimic suppressed proliferation and inhibited cell migration and invasion in HT-29 and LoVo colon cancer cell lines.
|
29399173 |
2018 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In the present study, we indicated that LINC00096 might promote the proliferation and invasion through regulating the miR-383-5p/RBM3 pathway in TNBC, which providing a novel therapeutic target for cancer treatment.
|
31819536 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
MicroRNA-383 suppresses cell proliferation and invasion in colorectal cancer by directly targeting paired box 6.
|
29512711 |
2018 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Subsequent functional study in HTR-8/SVneo and HUVEC cells indicated that MALAT1 modulates the cell proliferation, apoptosis, migration and invasion via directly interact with miR-383, miR-15, miR-205 and miR-375.
|
30173780 |
2018 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Long noncoding RNA HOXC13-AS positively affects cell proliferation and invasion in nasopharyngeal carcinoma via modulating miR-383-3p/HMGA2 axis.
|
30536950 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This study aims to evaluate the effect of the regulatory relationship between microRNA-383 (miR-383) and PARP2 in the cell migration and invasion in human with cervical cancer (CC) via the PI3K-AKT-MTOR signaling pathway.
|
29236322 |
2018 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Taken together, these findings uncover a novel regulatory mechanism for constitutive IGF1R signaling activation in glioma cancer and may provide miR-383 as a useful diagnostic marker or therapeutic target.
|
23564324 |
2013 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Due to its aberrant expression in some types of human cancer, miR-383 has the value of being investigated in relation to cancer treatment and diagnosis.
|
28243881 |
2017 |